enGene Therapeutics Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor
Community Key Opinion Leaders (KOLs) to present on real-world clinical decision making in high-risk non-muscle invasive bladder cancer (NMIBC)
Additional discussion to focus on preclinical data supporting
Data update on key regulatory endpoints, complete response (CR) at any time and maturing durability, as well as landmark CR rates from LEGEND's pivotal cohort planned for 4Q 2026
Pre-Biologics License Application
enGene Therapeutics Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor
enGene Therapeutics Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today announced that it will host a virtual key opinion leader (KOL) event on
Michael Heffernan assumes the role of Chairman of the Board
Dr. Richard Glickman to step down
Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026
Initiation of BLA submission for
The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.Rectify is developing oral
12-month complete response data from LEGEND pivotal cohort and subsequent FDA engagement planned for 2H 2026
Initiation of Biologics License Application (BLA) filing for detalimogene planned for 2H 2026
First
LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of enGene Therapeutics Inc. ("enGene"
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of enGene Therapeutics Inc. ("Engene" or the "Company") (NASDAQ:ENGN). Such investors are advised to
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of enGene Therapeutics Inc. ("Engene" or the "Company") (NASDAQ:ENGN). Such investors are advised to contact
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of enGene Therapeutics Inc. ("Engene" or the "Company") (NASDAQ:ENGN). Such investors are advised to
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of enGene Therapeutics Inc. ("Engene" or the "Company") (NASDAQ:ENGN). Such investors are advised to contact
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of enGene Therapeutics Inc. (NASDAQ:ENGN). The investigation focuses on enGene's executive
